These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 35914727)

  • 21. Humoral and Cellular Immune Response After Third and Fourth SARS-CoV-2 mRNA Vaccination in Liver Transplant Recipients.
    Harberts A; Schaub GM; Ruether DF; Duengelhoef PM; Brehm TT; Karsten H; Fathi A; Jahnke-Triankowski J; Fischer L; Addo MM; Haag F; Luetgehetmann M; Lohse AW; Schulze Zur Wiesch J; Sterneck M
    Clin Gastroenterol Hepatol; 2022 Nov; 20(11):2558-2566.e5. PubMed ID: 35850415
    [TBL] [Abstract][Full Text] [Related]  

  • 22. SARS-CoV-2-specific humoral and cell-mediated immune responses after immunization with inactivated COVID-19 vaccine in kidney transplant recipients (CVIM 1 study).
    Bruminhent J; Setthaudom C; Chaumdee P; Boongird S; Kiertiburanakul S; Malathum K; Nongnuch A; Phuphuakrat A; Jirasiritham S; Janphram C; Thotsiri S; Upama S; Assanatham M;
    Am J Transplant; 2022 Mar; 22(3):813-822. PubMed ID: 34657386
    [TBL] [Abstract][Full Text] [Related]  

  • 23. COVID-19 Vaccine in Lung and Liver Transplant Recipients Exceeds Expectations: An Italian Real-Life Experience on Immunogenicity and Clinical Efficacy of BNT162b2 Vaccine.
    Morlacchi LC; Alicandro G; Uceda Renteria S; Zignani N; Giacomel G; Rossetti V; Sagasta M; Citterio G; Lombardi A; Dibenedetto C; Antonelli B; Rosso L; Lampertico P; Ceriotti F; Blasi F; Donato MF
    Transpl Int; 2024; 37():12729. PubMed ID: 39050189
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impaired humoral and cellular response to primary COVID-19 vaccination in patients less than 2 years after allogeneic bone marrow transplant.
    Murray SM; Barbanti M; Campbell C; Brown A; Chen L; Dhanapal J; Tseu B; Pervaiz O; Peters L; Springett S; Danby R; Adele S; Phillips E; Malone T; Amini A; Stafford L; Deeks AS; Dunachie S; Klenerman P; Peniket A; Barnes E; Kesavan M
    Br J Haematol; 2022 Aug; 198(4):668-679. PubMed ID: 35655410
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety and immunogenicity of a live-attenuated influenza virus vector-based intranasal SARS-CoV-2 vaccine in adults: randomised, double-blind, placebo-controlled, phase 1 and 2 trials.
    Zhu F; Zhuang C; Chu K; Zhang L; Zhao H; Huang S; Su Y; Lin H; Yang C; Jiang H; Zang X; Liu D; Pan H; Hu Y; Liu X; Chen Q; Song Q; Quan J; Huang Z; Zhong G; Chen J; Han J; Sun H; Cui L; Li J; Chen Y; Zhang T; Ye X; Li C; Wu T; Zhang J; Xia NS
    Lancet Respir Med; 2022 Aug; 10(8):749-760. PubMed ID: 35644168
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Predominantly defective CD8
    Taus E; Shino MY; Ibarrondo FJ; Hausner MA; Hofmann C; Yang OO
    J Transl Med; 2023 Jun; 21(1):374. PubMed ID: 37291575
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Induction of High Levels of Specific Humoral and Cellular Responses to SARS-CoV-2 After the Administration of Covid-19 mRNA Vaccines Requires Several Days.
    Gil-Manso S; Carbonell D; López-Fernández L; Miguens I; Alonso R; Buño I; Muñoz P; Ochando J; Pion M; Correa-Rocha R
    Front Immunol; 2021; 12():726960. PubMed ID: 34671348
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cellular and humoral immune responses after a third dose of SARS-CoV-2 mRNA vaccine in lung transplant recipients in Japan.
    Ui M; Hirama T; Akiba M; Honda M; Kikuchi T; Okada Y
    Vaccine; 2023 Jul; 41(31):4534-4540. PubMed ID: 37328349
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pre-existing immunity to SARS-CoV-2 associates with strong T cell responses induced by inactivated COVID-19 vaccines.
    Yi X; Wang Y; Li Q; Li X; Zhang P; Fu X; Gu S; Zhang D; Liu X; Lou H; Wu Y; Tang L; Hou J; Li Y
    J Med Virol; 2023 Mar; 95(3):e28642. PubMed ID: 36890630
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of SARS-CoV-2 in Hematopoietic Stem Cell Transplantation and Chimeric Antigen Receptor T Cell Therapy Recipients.
    Mushtaq MU; Shahzad M; Chaudhary SG; Luder M; Ahmed N; Abdelhakim H; Bansal R; Balusu R; DeJarnette S; Divine C; Kribs R; Shune L; Singh AK; Ganguly S; Abhyankar SH; McGuirk JP
    Transplant Cell Ther; 2021 Sep; 27(9):796.e1-796.e7. PubMed ID: 34256172
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antibody response to SARS-CoV-2 mRNA vaccine among kidney transplant recipients: a prospective cohort study.
    Rozen-Zvi B; Yahav D; Agur T; Zingerman B; Ben-Zvi H; Atamna A; Tau N; Mashraki T; Nesher E; Rahamimov R
    Clin Microbiol Infect; 2021 Aug; 27(8):1173.e1-1173.e4. PubMed ID: 33957273
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials.
    Yang S; Li Y; Dai L; Wang J; He P; Li C; Fang X; Wang C; Zhao X; Huang E; Wu C; Zhong Z; Wang F; Duan X; Tian S; Wu L; Liu Y; Luo Y; Chen Z; Li F; Li J; Yu X; Ren H; Liu L; Meng S; Yan J; Hu Z; Gao L; Gao GF
    Lancet Infect Dis; 2021 Aug; 21(8):1107-1119. PubMed ID: 33773111
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of Donor and Recipient SARS-CoV-2 Vaccination or Infection on Immunity after Hematopoietic Cell Transplantation.
    Sherman AC; Cheng CA; Swank Z; Zhou G; Li X; Issa NC; Walt DR; Baden LR; Soiffer RJ
    Transplant Cell Ther; 2023 May; 29(5):337.e1-337.e5. PubMed ID: 36736784
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Past COVID-19 and immunosuppressive regimens affect the long-term response to anti-SARS-CoV-2 vaccination in liver transplant recipients.
    Toniutto P; Falleti E; Cmet S; Cussigh A; Veneto L; Bitetto D; Fornasiere E; Fumolo E; Fabris C; Sartor A; Peressutti R; Curcio F; Regattin L; Grillone L
    J Hepatol; 2022 Jul; 77(1):152-162. PubMed ID: 35283215
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Kinetics of the B- and T-Cell Immune Responses After 6 Months From SARS-CoV-2 mRNA Vaccination in Patients With Rheumatoid Arthritis.
    Farroni C; Picchianti-Diamanti A; Aiello A; Nicastri E; Laganà B; Agrati C; Castilletti C; Meschi S; Colavita F; Cuzzi G; Casetti R; Grassi G; Petrone L; Vanini V; Salmi A; Repele F; Altera AMG; Maffongelli G; Corpolongo A; Salemi S; Di Rosa R; Nalli G; Sesti G; Vaia F; Puro V; Goletti D
    Front Immunol; 2022; 13():846753. PubMed ID: 35309297
    [TBL] [Abstract][Full Text] [Related]  

  • 36. SARS-CoV-2-reactive antibody waning, booster effect and breakthrough SARS-CoV-2 infection in hematopoietic stem cell transplant and cell therapy recipients at one year after vaccination.
    Piñana JL; Martino R; Vazquez L; López-Corral L; Pérez A; Chorão P; Avendaño-Pita A; Pascual MJ; Sánchez-Salinas A; Sanz-Linares G; Olave MT; Arroyo I; Tormo M; Villalon L; Conesa-Garcia V; Gago B; Terol MJ; Villalba M; Garcia-Gutierrez V; Cabero A; Hernández-Rivas JÁ; Ferrer E; García-Cadenas I; Teruel A; Navarro D; Cedillo Á; Sureda A; Solano C;
    Bone Marrow Transplant; 2023 May; 58(5):567-580. PubMed ID: 36854892
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunogenicity of the BNT162b2 mRNA vaccine in heart transplant recipients - a prospective cohort study.
    Itzhaki Ben Zadok O; Shaul AA; Ben-Avraham B; Yaari V; Ben Zvi H; Shostak Y; Pertzov B; Eliakim-Raz N; Abed G; Abuhazira M; Barac YD; Mats I; Kramer MR; Aravot D; Kornowski R; Ben-Gal T
    Eur J Heart Fail; 2021 Sep; 23(9):1555-1559. PubMed ID: 33963635
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Humoral response and safety of the BNT162b2 and mRNA-1273 COVID-19 vaccines in allogeneic hematopoietic stem cell transplant recipients: An observational study.
    Nishikubo M; Shimomura Y; Maruoka H; Nasu S; Nishioka T; Sakizono K; Mitsuyuki S; Kubo T; Okada N; Nakagawa D; Kamijo K; Imoto H; Yamamoto R; Nagai Y; Hiramoto N; Yoshioka S; Yonetani N; Matsushita A; Miyakoshi C; Doi A; Ishikawa T
    J Infect Chemother; 2023 Mar; 29(3):274-280. PubMed ID: 36442827
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy of SARS-CoV-2 Vaccine Doses in Allogeneic Hemopoietic Stem Cell Recipients: A Systematic Review and Meta-Analysis.
    Rubin M; Suelzer E; Ulschmid C; Thapa B; Szabo A; Abid MB
    Asian Pac J Cancer Prev; 2024 Feb; 25(2):393-399. PubMed ID: 38415523
    [TBL] [Abstract][Full Text] [Related]  

  • 40. SARS-CoV-2 vaccination in the first year after allogeneic hematopoietic cell transplant: a prospective, multicentre, observational study.
    Hill JA; Martens MJ; Young JH; Bhavsar K; Kou J; Chen M; Lee LW; Baluch A; Dhodapkar MV; Nakamura R; Peyton K; Shahid Z; Armistead P; Westervelt P; McCarty J; McGuirk J; Hamadani M; DeWolf S; Hosszu K; Sharon E; Spahn A; Toor AA; Waldvogel S; Greenberger LM; Auletta JJ; Horowitz MM; Riches ML; Perales MA
    EClinicalMedicine; 2023 May; 59():101983. PubMed ID: 37128256
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.